This company has a lot of cash, page-2

Hi Tallguy, IBA looks to be a good buy at current price of 0.12c, with a little over 163 Million FPO shares on issue and cash in the bank of over A$21,200,000 equates to 12.9c per share in cash. I would suggest that it would be well worth keeping an eye on this one.

Fig Jam I don't hold IBA

IBA HEALTH LIMITED 2002-06-18 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
* Automated healthcare information system delivers health care
professionals access to timely, accurate information on patients,
improved workflow and efficiency, and reduces risk of medication
errors.
* Patient care is significantly enhanced.
* Ibaclinical presents significant growth opportunities for IBA.

IBA Health Limited (ASX: IBA), Australia's leading health information
systems company, expects a positive response to ibaclinical, an
automated healthcare information system which significantly improves
patient care and safety while improving operational efficiencies.

"The health industry continues to struggle with manual processes
creating inefficiencies and endangering patient care," IBA Health
Executive Chairman, Mr Gary Cohen said. "Health is an information
intensive industry and the market has started to focus on improving
these manual processes."

"The demand for timely access to accurate information particularly
across a fragmented health system, and for tools to reduce variations
in care treatment and medication errors, has led demand for an
all-in-one solution. That solution is ibaclincial".

"ibaclinical provides easy, rapid access to patient information for
both onsite and remote clinicians, enhancing decision making
capabilities, decreasing costs and supporting more effective patient
care."

Data can also flow from other sources into the ibaclinical system.
Information such as results, history, physicals, and assessments can
be viewed from a single system allowing clinicians to view patient
information prior to taking any actions, such as ordering tests. In
addition, decision support is provided through complex duplicate
checking, alerting clinicians to the fact that the patient may be
allergic to drugs or avoiding the reordering of an existing test.

"The market for ibaclinical is potentially worldwide" Mr Cohen said.
Currently, IBA Health is installing ibaclinical in sites in United
Kingdom, Singapore and Australia. "IBA Health sees significant
international sales opportunities with ibaclinical which has the
advantage of sitting alongside legacy administration systems".

Mr Cohen said ibaclinical was further proof of IBA Health's status as
an e-health pioneer. "This product suite builds on ibaPAS, solutions
for patient administration and ibafinancial, solutions for business
management. IBA Health is uniquely positioned to benefit from the
every increasing focus within the health community on how to improve
patient outcomes, improve efficiency, and lower costs through the
provision of information systems."

As reported to the market on 5 June 2002, IBA Health has
substantially reduced operational costs while increasing revenue. At
31 May 2002, IBA had cash reserves exceeding $21.2 million with no
borrowings. IBA costs, including development expenditure have been
reduced by $15 million as annualised from 30 June 2002, partly as a
result of InHealth transaction and the operational restructuring.

ABOUT IBA HEALTH LIMITED

For more information on IBA, please visit the company's website at
www.ibatech.com

Gary Cohen
EXECUTIVE CHAIRMAN
+61 2 8251 6700
[email protected]